Clinical Trials Logo

Overactive Bladder clinical trials

View clinical trials related to Overactive Bladder.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06181019 Active, not recruiting - Overactive Bladder Clinical Trials

Acupuncture Combined With Mirabegron in the Treatment of OAB

ACWMITTOOAB
Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

Introduction: As conventional treatments for overactive bladder (OAB) have not yet shown satisfactory results, new approaches are needed. Therefore, this study aimed to investigate the efficacy and safety of acupuncture combined with mirabegron for the treatment of OAB. Methods: This prospective cohort study enrolled 80 OAB patients who were then divided into control and treatment groups using a randomized number-table method. The control group was administered mirabegron alone (50 mg/day), while the treatment group was administered mirabegron orally along with acupuncture at the following points: guanyuan (CV4), zhongji (CV3), and sanyinjiao (SP6). The OAB symptom score (overactive bladder syndrome score [OABSS]), voiding, urgency, nocturia, incontinence, and incidence of related adverse events were compared between the two groups at baseline and after 4, 8, and 12 weeks of treatment.

NCT ID: NCT05494567 Active, not recruiting - Overactive Bladder Clinical Trials

Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Start date: November 8, 2021
Phase: Phase 4
Study type: Interventional

The investigators will compare the efficacy and safety of tadalafil/solifenacin combination therapy versus tamsulosin/solifenacin combination therapy for the treatment of BPH/OAB in a randomized controlled trial (RCT).

NCT ID: NCT05308979 Active, not recruiting - Overactive Bladder Clinical Trials

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.

NCT ID: NCT05282069 Active, not recruiting - Overactive Bladder Clinical Trials

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Start date: May 12, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder.

NCT ID: NCT05241379 Active, not recruiting - Overactive Bladder Clinical Trials

AURA-2: Augmenting Urinary Reflex Activity

AURA-2
Start date: November 30, 2022
Phase: N/A
Study type: Interventional

AMBER AURA-2 study (Augmenting Urinary Reflex Activity 2) is a short-duration (6 month) safety and electrophysiological study using an implanted Amber UI system and two electrode leads to provide closed-loop pudendal nerve stimulation for the treatment of urinary incontinence.

NCT ID: NCT05226286 Active, not recruiting - Overactive Bladder Clinical Trials

Evaluation of Implantable Tibial Neuromodulation Pivotal Study

TITAN 2
Start date: January 31, 2022
Phase: N/A
Study type: Interventional

The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.

NCT ID: NCT05067478 Active, not recruiting - Overactive Bladder Clinical Trials

Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)

Start date: October 28, 2021
Phase:
Study type: Observational

This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.

NCT ID: NCT04936464 Active, not recruiting - Overactive Bladder Clinical Trials

Transcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence

TTeNS
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

This is a single-center, double-blinded, randomized controlled trial evaluating the efficacy of TTNS versus a sham intervention. Both interventions will be performed by participants in their homes after standardized instruction. The primary outcome is a comparison of the mean change in OAB-q scores before and after treatment between the intervention and control groups. Changes in the number of urgency incontinence episodes and an estimation of cost effectiveness will additionally be measured. Intention to treat analysis will be performed.

NCT ID: NCT04113941 Active, not recruiting - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

Start date: August 23, 2019
Phase: Phase 3
Study type: Interventional

This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.

NCT ID: NCT03556891 Active, not recruiting - Overactive Bladder Clinical Trials

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Start date: September 4, 2018
Phase: N/A
Study type: Interventional

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.